Evidence map›Paper›PMID 39930169›Full record

ReviewAdvances in experimental medicine and biology2025

Cellular Senescence: An Emerging Player in the Pathogenesis of AMD.

Vilas Wagh, Nivedita Damodaren, Sharad K Mittal, Fabian L Cardenas-Diaz, Hong Sun, Alexander V Loktev, Vanessa M Peterson, Janmeet S Saini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vilas WaghData AI and Genome Sciences, Merck & Co., Inc., Cambridge, MA, USA.
Nivedita DamodarenData AI and Genome Sciences, Merck & Co., Inc., Cambridge, MA, USA.
Sharad K MittalData AI and Genome Sciences, Merck & Co., Inc., Cambridge, MA, USA.
Fabian L Cardenas-DiazData AI and Genome Sciences, Merck & Co., Inc., Cambridge, MA, USA.
Hong SunData AI and Genome Sciences, Merck & Co., Inc., Cambridge, MA, USA.
Alexander V LoktevRetinal and Vascular Biology, Cardiometabolic Diseases, Merck & Co., Inc., South San Francisco, CA, USA.
Vanessa M PetersonData AI and Genome Sciences, Merck & Co., Inc., Cambridge, MA, USA.
Janmeet S SainiData AI and Genome Sciences, Merck & Co., Inc., Cambridge, MA, USA. janmeet.saini@merck.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is the leading cause of blindness in the aged population. The accumulation of abnormal extracellular drusen deposits between the retinal pigment epithelium (RPE) and Bruch's membrane is a significant driver of AMD pathology. Drusen deposition leads to the degeneration of RPE cells and, subsequently, photoreceptors, driving the disease to its advanced stages and ultimately resulting in complete vision loss. Although the exact mechanisms underlying the AMD pathogenesis are not fully understood, it is hypothesized that the disease begins with the dysfunction of the RPE, triggering the complement and pro-inflammatory cascade. Over the last decade, new findings have implicated the involvement of cellular senescence (CS) in the pathology of age-related disorders. Specifically for AMD, evidence suggests that the senescence of RPE cells may play a role in the pathogenesis of the disease. In this review, we discuss the potential role of senescence in the onset and progression of AMD and propose potential therapeutic interventions that could be developed by targeting senescence.

Indexed as

Cellular SenescenceMacular DegenerationRetinal Pigment EpitheliumAnimalsBruch MembraneHumansRetinal DrusenAge-related macular degeneration (AMD)AgingCellular senescenceDrusenPathogenesisRetinaRetinal pigment epithelium (RPE)Therapeutics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.